Oklahoma Senate Bill SB1548

Oklahoma 2026 Regular Session

• Introduced: 2/2/26
• Refer: 2/3/26

Caption

Civil liability; making vaccine manufacturer liable under certain conditions; directing certain relief. Effective date.

Summary

SB1548 creates a new civil liability cause of action against vaccine manufacturers when they advertise a vaccine in Oklahoma and the advertised vaccine causes harm or injury to an individual. The bill defines “advertise” broadly to include television, radio, print, internet, digital and electronic media, product placement, influencer promotions, and other paid promotion, but it excludes ordinary communications between health care providers and patients and promotional materials displayed in clinical settings. The bill also sets a three-year statute of limitations for bringing an action, measured from when the cause of action accrues. If a claimant prevails, the court must award actual damages, court costs, and reasonable attorney fees. The measure would be codified as a new section in Title 76 of the Oklahoma Statutes and would take effect November 1, 2026.

Impact

SB1548 would expand Oklahoma civil liability law by creating a specific statutory remedy tied to vaccine advertising and alleged resulting injury, placing vaccine manufacturers at risk of direct lawsuits under state law. It would add a new cause of action, a defined limitations period, and mandatory fee-shifting and damages provisions, affecting vaccine manufacturers, injured individuals, and potentially health care and pharmaceutical advertising practices in the state.

Sentiment

The available legislative context shows limited public or committee discussion and no recorded votes, so there is no strong evidence of broad support or opposition from the provided materials. The bill’s referral to the Health and Human Services committee suggests it was treated as a health-policy measure, but the absence of transcripts or vote history means sentiment cannot be measured beyond the bill’s introduction and referral stage.

Contention

The main point of contention is likely the bill’s targeted liability rule for vaccine manufacturers, especially because it ties liability to advertising and vaccine-related injury in a way that could be viewed as unusual or expansive. Supporters would likely frame it as consumer protection and accountability, while opponents may argue it could discourage vaccine promotion, increase litigation, and conflict with existing federal or state vaccine-liability frameworks. The bill’s broad definition of advertising, combined with mandatory attorney fees and damages, is another likely source of dispute.